The US Secretary of Health and Human Services, Kathleen Sebelius, has announced that the Department will take important steps necessary to prepare for potential commercial-scale production of a candidate vaccine for the novel influenza A ( H1N1; Marketletters passim). The Secretary is directing approximately $1.0 billion in existing funds that will be used for clinical studies that will take place over the summer and for commercial-scale production of two potential vaccine ingredients for the pre-pandemic influenza stockpile.
Ms Sebelius said: "preparation and planning are critical to keep Americans safe in the face of a potential pandemic." She added: "our goal throughout this new H1N1 outbreak has been to stay one step ahead of the virus. An important part of this effort has been our work to develop a potential vaccine because vaccines can help prevent and control influenza virus outbreaks."
New orders placed via existing flu vaccine contracts
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze